|
|
![]() Stay on Course with Your Treatment It is recommended that patients receive DOXIL treatments by intravenous (IV) infusion once every four weeks for a minimum of four courses. Four courses of DOXIL therapy are recommended as long as your disease does not progress, and you continue to tolerate treatment because clinical trials have shown this is the median time to response. It’s also critical to be vigilant in monitoring your body for signs and symptoms of hand-foot syndrome (HFS). Intervention at the first appearance of symptoms can help minimize the extent, severity, and degree to which HFS disrupts the use of DOXIL. You should always speak to your healthcare team about your treatment and any questions or concerns you may have. And be sure to ask your healthcare team about resources. The oncology nurses are an invaluable resource, as are support groups, advocacy organizations, Web sites that offer reliable, useful information, or any other educational information that can help you stay on course with your treatment. Stay on Course with Your Life
For more information, see Cancer and Intimacy Diet and Exercise
It is also a good idea while taking DOXIL to avoid spicy and acidic foods to help prevent stomatitis (mouth sores). Be sure to consult your physician before attempting any of these recommendations. Emotional Well Being And remember, you are not alone. You can find great support through community groups and the Community Connection. |
|
|
Doxil (doxorubicin HCl), is a prescription medicine that is administered intravenously by your healthcare professional. DOXIL is used to treat patients with ovarian cancer that has progressed or recurred after platinum-based chemotherapy. Please read Important Safety Information below, and talk to your healthcare professional to learn more about DOXIL. Important Safety Information Serious and possibly permanent heart-related side effects that may lead to congestive heart failure can occur in patients treated with DOXIL. Inform your doctor of any history of heart disease, radiation to your chest, or prior chemotherapy. Your doctor may monitor your heart function.Infusion reactions may occur during administration. Be sure to tell your doctor if you have any symptoms during infusion, including: flushing, shortness of breath, facial swelling, headaches, chills, back pain, tightness in your chest or throat, dizziness, or lightheadedness. For most patients, these reactions have resolved within several hours to a day once the infusion is stopped, or for some patients with slowing of the infusion rate. However, in some cases, these reactions may be serious and sometimes life threatening, though they are rarely fatal. DOXIL may severely reduce the number of blood cells (red blood cells, white blood cells, and platelets) in your body. Your doctor may adjust or delay your dose of DOXIL if this occurs. Your doctor may adjust your dose of DOXIL if you have liver problems. You should not take DOXIL if you are nursing. If you are pregnant or are planning to become pregnant, inform your doctor. You should not take DOXIL if you are allergic to doxorubicin HCI or the components of DOXIL. The most common side effects of DOXIL are:
Be sure to tell your doctor immediately if you experience any of these or other symptoms. DOXIL may make the side effects of other anticancer therapies worse when used in combination. Following administration, DOXIL may turn urine and other bodily fluids a reddish-orange color. This is due to the color of DOXIL and will go away as the drug leaves the body. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088 (1-800-332-1088). Please click here for full Product Information in PDF format,for more details. |
This site is published by Centocor Ortho Biotech Products, L.P. which is solely responsible for its contents. © Centocor Ortho Biotech Products, L.P. 2003-2010 Last modified on:Dec 03 2009 at 10:48:01 EST |
![]() |




